Lynn Wang, MD, PhD, FCAP
Professor, Division of Genomic and Molecular Pathology
Founding Medical Director
Genomic and Molecular Pathology
University of Chicago Medical Center
Chicago, IL, USA
What is the range of mutational rearrangements and alterations that can be identified by hybrid capture-based NGS and that have clinical applications?
What is the rationale for using genome-wide NGS in the setting of precision cancer medicine?
What is the rationale for using genome-wide NGS in the setting of precision cancer medicine?
What kind of tissue samples and cellularity are required for accurate and actionable NGS?
What kind of tissue samples and cellularity are required for accurate and actionable NGS?
What specific information, variances, actionable guidance, and clinical/biological interpretations are provided on a NGS pathology report? How do you deal with uncertainties and variations of unknown significance? And with frame shifts?